Roflumilast Foam Looks Promising in Seborrheic Dermatitis Trial
Roflumilast is a highly potent and selective phosphodiesterase type 4 inhibitor.
Pruritus And Dry Skin
Dupilumab Gets Priority Review for Prurigo Nodularis
The sBLA is supported by data from the phase 3 PRIME2 and PRIME trials that assessed dupilumab in patients 18 years of age and older with prurigo nodularis.
Optimal Difelikefalin Dose Reported for Pruritus in Hemodialysis
In a previous US phase 2 trial, no clear dose response was observed with difelikefalin.
Significant Improvements Observed With Dupilumab in Prurigo Nodularis Trial
The phase 3 PRIME study evaluated dupilumab in 151 adults with inadequately controlled prurigo nodularis.
New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Dupilumab Reduced Itch, Skin Lesions in Patients With Prurigo Nodularis
The randomized, double-blind, placebo-controlled, parallel-group PRIME2 study included 160 patients with prurigo nodularis.
Korsuva Approved for Chronic Kidney Disease-Associated Pruritus
The approval was based on data from the pivotal phase 3 KALM-1 and KALM-2 trials, as well as data from an additional 32 clinical studies.
MPR Weekly Dose Podcast Episode 87
This week we have news of the FDA requesting a change to statin prescribing labels, a new vaccine for streptococcus pneumoniae, a new plaque psoriasis cream, a stem cell therapy gets fast tracked as a possible Parkinson disease treatment, and there’s a new treatment approved for Progressive Familial Intrahepatic Cholestasis.
Bylvay Approved for Progressive Familial Intrahepatic Cholestasis
Bylvay is an oral reversible inhibitor of the ileal bile acid transporter.
Sarna Eczema Relief Whipped Foam Now Available
The whipped foam formulation allows for rapid absorption to provide fast relief.
